MedTrace Logo

Allogeneic Stem Cell Therapy in Heart Failure

NCT03092284 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2022-09-06

No results posted yet for this study

Summary

The present aim is to perform at clinical double-blind placebo-controlled Cardiology Stem Cell Centre - Adipose Stem Cells (CSCC\_ASC) study in heart failure patients to investigate the regenerative capacity of the CSCC\_ASC treatment.

Conditions

Interventions

BIOLOGICAL

Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)

Direct intramyocardial injection of CSCC\_ASC

BIOLOGICAL

Placebo

Saline

Sponsors & Collaborators

  • JKastrup

    lead OTHER

Principal Investigators

  • Jens Kastrup, Professor MD · Rigshospitalet, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2021-07-31
Completion
2022-07-31

Countries

  • Denmark

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03092284 on ClinicalTrials.gov